Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Reactogenicity, Tolerability, Immunogenicity and Efficacy of Live Attenuated ETEC ACE527 Vaccine Administered Alone or With a Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Volunteers

NCT01739231 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT01739231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01739231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Reactogenicity, Tolerability, Immunogenicity and Efficacy of Live Attenuated ETEC ACE527 Vaccine Administered Alone or With a Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Volunteers
Lead sponsor
PATH
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2012
Completion date
January 31, 2014
Enrollment
81 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diarrhea